LV12603B - Paņēmiens hiperproliferatīvo vaskulāro slimību ārstēšanai, lietojot rapamicīnu, iespējams, kombinācijā ar mikofenolskābi - Google Patents

Paņēmiens hiperproliferatīvo vaskulāro slimību ārstēšanai, lietojot rapamicīnu, iespējams, kombinācijā ar mikofenolskābi Download PDF

Info

Publication number
LV12603B
LV12603B LVP-00-134A LV000134A LV12603B LV 12603 B LV12603 B LV 12603B LV 000134 A LV000134 A LV 000134A LV 12603 B LV12603 B LV 12603B
Authority
LV
Latvia
Prior art keywords
vascular
rapamycin
hyperproliferative
disease
vascular disease
Prior art date
Application number
LVP-00-134A
Other languages
English (en)
Other versions
LV12603A (en
Inventor
Randall Ellis MORRIS
Clare Robert Gregory
Original Assignee
American Home Products Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corporation filed Critical American Home Products Corporation
Publication of LV12603A publication Critical patent/LV12603A/xx
Publication of LV12603B publication Critical patent/LV12603B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Claims (12)

  1. LV 12603 FORMULA 1. Rapamicīna lietošana medikamenta ražošanai, kurš aizsargā no vai ārstē hiperproliferatīvu vaskulāro slimību zīdītājiem, kur minētā hiperproliferatīvā slimība ir radusies vai var rasties no mehāniska asinsvadu ievainojuma.
  2. 2. Lietošana saskaņā ar 1. punktu, kur medikaments ir piemērots orālai, parenterālai, intravaskulārai, intranazālai, intrabronhiālai, transdermālai, rektālai ievadīšanai, vai ievadīšanai caur stentu, piesātinātu ar rapamicīnu.
  3. 3. Lietošana saskaņā ar 1. vai 2. punktu, kur medikaments satur mikofenolskābi vienlaicīgai, atsevišķai vai secīgai ievadīšanai.
  4. 4. Lietošana saskaņā ar jebkuru no punktiem 1 līdz 3, kur minētā hiperproliferatīvā vaskulārā slimība var būt iekšējo (intīma) gludo musku|u šūnu hiperplāzija, restenoze un vaskulārā oklūzija.
  5. 5. Lietošana saskaņā ar jebkuru no punktiem 1 līdz 3, kur hiperproliferatīvā vaskulārā slimība ir restenoze.
  6. 6. Lietošana saskaņā ar jebkuru no punktiem 1 līdz 3, kur rapamicīnu ir jāievada vienlaicīgi ar un/vai pēc tam, kad minētais zīdītājs tiek pakļauts transdermālai transluminālai koronārai angioplastikas procedūrai.
  7. 7. Lietošana saskaņā ar 4. punktu, kur mehāniskais asinsvada ievainojums var būt vaskulārā katetrizācija, vaskulārs ieskrāpējums, transdermāla transluminālā koronārā angioplastika, vaskulārā ķirurģija un ārstēšana ar lāzeru.
  8. 8. Produkts, kurš satur rapamicīnu un mikofenolskābi kā kombinētu maisījumu vienlaicīgai, atsevišķai vai secīgai lietošanai, lai aizsargātu no vai ārstētu hiperproliferatīvo vaskulāro slimību.
  9. 9. Produkts saskaņā ar 8. punktu, kur hiperproliferatīvā vaskulārā slimība var būt iekšējo (intima) gludo muskuļu šūnu hiperplāzija, restenoze un vaskulārā oklūzija. 2
  10. 10. Produkts saskaņā ar 8 vai 9 punktu, kur hiperproliferatīvā vaskuiārā slimība ir restenoze.
  11. 11. Produkts saskaņā ar 9. punktu, kur hiperproliferatīvā vaskuiārā slimība ir radusies vai var rasties no mehāniska asinsvadu ievainojuma kā vaskulāras katetrizācijas, vaskulāra ieskrāpējuma, transdermālas transluminālas koronārās angioplastikas, vaskulāras ķirurģijas un ārstēšanas ar lāzeru.
  12. 12. Farmaceitiska kompozīcija, kura satur rapamicīnu, mikofenolskābi un farmaceitiski pieņemamu nesēju.
LVP-00-134A 1992-01-09 2000-10-06 Paņēmiens hiperproliferatīvo vaskulāro slimību ārstēšanai, lietojot rapamicīnu, iespējams, kombinācijā ar mikofenolskābi LV12603B (lv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81931492A 1992-01-09 1992-01-09

Publications (2)

Publication Number Publication Date
LV12603A LV12603A (en) 2001-01-20
LV12603B true LV12603B (lv) 2001-04-20

Family

ID=25227805

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-00-134A LV12603B (lv) 1992-01-09 2000-10-06 Paņēmiens hiperproliferatīvo vaskulāro slimību ārstēšanai, lietojot rapamicīnu, iespējams, kombinācijā ar mikofenolskābi

Country Status (14)

Country Link
EP (1) EP0551182B1 (lv)
JP (1) JP2644955B2 (lv)
KR (1) KR100276142B1 (lv)
AT (1) ATE194493T1 (lv)
AU (1) AU665041B2 (lv)
CA (1) CA2086642C (lv)
DE (1) DE69328981T2 (lv)
DK (1) DK0551182T3 (lv)
ES (1) ES2147740T3 (lv)
GR (1) GR3034479T3 (lv)
LV (1) LV12603B (lv)
NZ (1) NZ245630A (lv)
PT (1) PT551182E (lv)
SG (1) SG47639A1 (lv)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
EP1155689B1 (en) 1993-07-19 2006-09-20 Angiotech Pharmaceuticals, Inc. Anti-angiogenic stents and methods of their preparation
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
WO1995014023A1 (en) * 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5444072A (en) * 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
EP0833828B1 (en) 1995-06-09 2002-11-20 Novartis AG Rapamycin derivatives
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
KR100616020B1 (ko) * 1996-03-27 2007-01-31 노파르티스 아게 맥관장애및이종이식술에서의라파마이신유도체의용도
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
IT1289815B1 (it) 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6273913B1 (en) † 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
WO1999055396A1 (en) 1998-04-27 1999-11-04 Surmodics, Inc. Bioactive agent release coating
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US6702849B1 (en) 1999-12-13 2004-03-09 Advanced Cardiovascular Systems, Inc. Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers
ES2243556T3 (es) 2000-10-16 2005-12-01 Conor Medsystems, Inc. Dispositivo medico expandible para proporcionar un agente beneficioso.
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
EP1449546B1 (en) 2003-02-21 2010-10-27 Sorin Biomedica Cardio S.R.L. A process for producing stents and corresponding stent
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
US7303758B2 (en) * 2004-01-20 2007-12-04 Cordis Corporation Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury
US20050220841A1 (en) 2004-04-06 2005-10-06 Dewitt David M Coating compositions for bioactive agents
USD516723S1 (en) 2004-07-06 2006-03-07 Conor Medsystems, Inc. Stent wall structure
US8192483B2 (en) 2005-10-06 2012-06-05 Kaneka Corporation Stent to be placed in the living body
EP2046410B1 (de) 2006-07-03 2019-04-10 Hemoteq AG Herstellung, verfahren und verwendung von wirkstofffreisetzenden medizinprodukten zur permanenten offenhaltung von blutgefässen
CA2673991C (en) 2007-01-21 2012-02-07 Hemoteq Ag Methods for coating catheter balloons with a defined quantity of active agent
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
WO2009089549A1 (en) 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
ES2550634T3 (es) 2009-07-10 2015-11-11 Boston Scientific Scimed, Inc. Uso de nanocristales para un balón de suministro de fármaco
EP2453938B1 (en) 2009-07-17 2015-08-19 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
US8889211B2 (en) 2010-09-02 2014-11-18 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
WO2013022458A1 (en) 2011-08-05 2013-02-14 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
JP6278332B2 (ja) 2013-04-22 2018-02-14 スズキ株式会社 変速機の制御装置

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus

Also Published As

Publication number Publication date
GR3034479T3 (en) 2000-12-29
ATE194493T1 (de) 2000-07-15
CA2086642A1 (en) 1993-07-10
ES2147740T3 (es) 2000-10-01
DE69328981D1 (de) 2000-08-17
AU3107993A (en) 1993-07-15
NZ245630A (en) 1997-07-27
EP0551182A1 (en) 1993-07-14
PT551182E (pt) 2000-12-29
CA2086642C (en) 2004-06-15
JPH069390A (ja) 1994-01-18
EP0551182B1 (en) 2000-07-12
DE69328981T2 (de) 2000-11-16
KR100276142B1 (ko) 2001-02-01
AU665041B2 (en) 1995-12-14
DK0551182T3 (da) 2000-10-09
SG47639A1 (en) 1998-04-17
KR930016102A (ko) 1993-08-26
HK1010332A1 (en) 1999-06-17
LV12603A (en) 2001-01-20
JP2644955B2 (ja) 1997-08-25

Similar Documents

Publication Publication Date Title
LV12603B (lv) Paņēmiens hiperproliferatīvo vaskulāro slimību ārstēšanai, lietojot rapamicīnu, iespējams, kombinācijā ar mikofenolskābi
US5646160A (en) Method of treating hyperproliferative vascular disease with rapamycin and mycophenolic acid
US5283257A (en) Method of treating hyperproliferative vascular disease
CA2094858C (en) Method of treating hyperproliferative vascular disease
US5288711A (en) Method of treating hyperproliferative vascular disease
US5021404A (en) Angiostatic collagen modulators
AU659868B2 (en) Method of treating immunoinflammatory disease
EP0583925A1 (en) Rapamycin for the treatment of Crohn's disease, ulcerative colitis or ulcerative proctitis
HK1010332B (en) Method of treating hyperproliferative vascular disease using rapamycin, eventually in combination with mycophenolic acid
EP1562590A2 (en) Compounds, methods and devices for inhibiting neoproliferative changes in blood vessel walls
HK1010333B (en) Use of rapamycin in the manufacture of a medicament for preventing and heating hyperproliferactive vascular diseases, eventually in combination with mycophenolic acid